China & US Lead Surge in Early-Stage Drug Development: New Research

The landscape of early-stage pharmaceutical innovation is undergoing a significant shift, with a new analysis revealing a marked increase in drug development activity in China. Whereas the United States remains the leading originator of early-stage drug programs, its dominance has lessened over the past decade as China’s contributions have grown substantially. This evolving dynamic has implications for global health, investment, and the future of medical breakthroughs.

Researchers at Georgetown University, publishing their findings in JAMA, examined global biopharmaceutical development programs between 2015 and 2025. Their analysis, utilizing data from the Clarivate Cortellis Drug Development Database, showed that the total number of early-stage programs—those in discovery, preclinical development, or early clinical testing—nearly doubled, rising from 10,417 in 2015 to 18,999 in 2024, an 82.4% increase. The study highlights a move away from a U.S.-centered model towards a dual-hub system with the United States and China at its core.

A Decade of Change: U.S. Share Declines, China’s Rises

In 2015, the U.S. Accounted for approximately 48% of all early-stage drug programs, while China contributed 8%. By 2024, the U.S. Share had decreased to just over 37%, while China’s share surged to over 32%. This represents a 641% increase in Chinese-origin programs, growing from 829 in 2015 to 6,145 in 2024. The growth wasn’t limited to these two nations; early-stage development expanded across multiple countries, but the expansion was most pronounced in China.

So-Yeon Kang, Ph.D., MBA, assistant professor in the Department of Health Management and Policy at the Georgetown University School of Health and member of Lombardi Comprehensive Cancer Center, emphasized the importance of understanding where innovation originates. “Understanding where that innovation originates is essential for countries thinking strategically about regulatory coordination, workforce development, and long-term patient access to new therapies,” she stated.

What Drives the Shift?

The reasons behind this shift are multifaceted. Recent reports, including one from CNBC, point to substantial state investment in China’s biotech ecosystem, a growing talent pool, and accelerated regulatory reforms as key drivers. These factors have created a more favorable environment for early-stage drug development, attracting both domestic and international investment. The FDA Commissioner Marty Makary has also warned that the U.S. Is facing bottlenecks in hospital contracting, ethical reviews, and the Investigational New Drug (IND) application process, hindering its ability to compete effectively.

Yunan Ji, Ph.D., professor at Georgetown University’s McDonough School of Business, noted that the changes reflect structural shifts in scientific discovery. “Where early-stage development happens shapes where capital flows, which companies attract investment, and ultimately which drugs reach patients—making these patterns critical for policymakers and investors to monitor.”

Defining Early-Stage Development and the Scope of the Study

It’s important to understand what constitutes “early-stage” drug development in the context of this research. The Georgetown University team defined it as the development of a specific drug for a specific indication, encompassing discovery, preclinical development, and early clinical testing. Programs were assigned to a country based on the global headquarters of the originating company, and this assignment remained consistent even after licensing or acquisition. This methodology provides a clearer picture of where the initial scientific discovery takes place, as opposed to where later-stage development or manufacturing might occur.

Implications for Global Healthcare and Innovation

The rise of China as a major hub for early-stage drug development has significant implications for the global healthcare landscape. A more diversified approach to innovation, as highlighted by Life Technology, can mitigate risks associated with centralized research models and foster a more resilient pharmaceutical industry. However, it also raises questions about intellectual property protection, regulatory harmonization, and the potential for increased competition.

The study’s authors emphasize that continued monitoring of these trends is crucial for policymakers. Effective financial and regulatory incentives will be needed to maintain a competitive edge and ensure that patients around the world have access to innovative therapies. The evolving two-hub system will also impact the flow of scientific talent and capital investment, requiring careful consideration from both governments and the private sector.

What’s Next: Monitoring and Adaptation

The researchers suggest that ongoing surveillance of global drug development trends is essential. This includes tracking not only the overall number of programs but also their distribution by development stage, drug modality (e.g., minor molecules, biologics), and therapeutic area. Policymakers will need to assess the effectiveness of existing incentives and consider new strategies to promote innovation and attract investment. Further research is also needed to understand the specific factors driving China’s success and to identify potential challenges and opportunities for collaboration between the U.S. And China.